PAD is a joint initiative between Novo Nordisk Foundation, Open Philanthropy and Bill & Melinda Gates Foundation, founded to catalyse the discovery and early development of antiviral medicines for the next pandemic and, ultimately, save lives.
Airfinity tracks and analyses over 500 antiviral candidates across 3 pathogen families (coronaviridae, paramyxovirus and orthomyxovirus), most of which are currently in development for SARS-CoV-2 treatment, in addition to Influenza and Nipah.
Our detailed analysis into research, development and the funding landscape helps decision makers get answers to time-sensitive and critical questions, including: → Which government agencies and nonprofit organisations are investing heavily in antiviral research and procurement for viruses of pandemic potential? → Which countries and organisations/funding bodies are ranking the highest for antiviral research performance? → Which antiviral target are being investigated across different viral pathogens? → What are the key drives of antiviral demand and uptake?